Sorrento Therapeutics announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve ablating drug candidate, resiniferatoxin or RTX, for the treatment of pain from osteoarthritis in the knee received treatment on July 31, 2018. In a planned safety assessment, the data monitoring committee found no safety concerns, and the study will continue as planned.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.